OncoMatch/Clinical Trials/NCT06920251
Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
Is NCT06920251 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Letermovir for relapsed refractory multiple myeloma (rrmm).
Treatment: Letermovir — This is an open-label, single arm, multicenter study to evaluate the efficacy of letermovir in the prevention of clinically significant CMV infection in adult, CMV-seropositive relapsed/refractory MM patients undergoing BsAbs therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
Subject must have received at least one proteasome inhibitor
Must have received: immunomodulatory drug
Subject must have received at least one immunomodulatory drug
Must have received: anti-CD38 antibody
Subject must have received at least one anti-CD38 antibody
Cannot have received: allogeneic stem cell transplantation
Exception: allowed if >1 year prior and no active GVHD and off immunosuppressants
Subject has previously received allogeneic stem cell transplantation within a year during prior therapy. Patients who received allogeneic stem cell transplantation should not have evidence of active graft-versus-host disease (GVHD) and off any immunosuppressants.
Cannot have received: autologous stem cell transplantation
Exception: allowed if >12 weeks prior
received autologous stem cell transplantation within 12 weeks of initiating study treatment
Cannot have received: plasmapheresis
Exception: allowed if >28 days prior
Plasmapheresis within the last 28 days of initiating study treatment
Cannot have received: major surgery
Exception: allowed if >28 days prior
Major surgery (as defined by the investigator) within 28 days of initiating study treatment
Lab requirements
Blood counts
Absolute neutrophil count (ANC) < 1,000/µL; Platelet count < 25,000/µL
Kidney function
Estimated glomerular filtration rate (eGFR) < 30 mL/min or requiring dialysis
Liver function
Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN); Serum total bilirubin > 1.5 × ULN, or for participants with documented Gilbert's syndrome > 3.0 mg/dL
Cardiac function
LVEF < 40% as determined by a MUGA scan or echocardiography; Prolonged QT syndrome (or QTcF >470 msec at screening); acute myocardial infarction or acute coronary syndromes within 6 months; clinically significant cardiac arrhythmias; thromboembolic or cerebrovascular events within 6 months
Absolute neutrophil count (ANC) < 1,000/µL. Platelet count < 25,000/µL. Estimated glomerular filtration rate (eGFR) < 30 mL/min or requiring dialysis. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN) Serum total bilirubin > 1.5 × ULN, or for participants with documented Gilbert's syndrome > 3.0 mg/dL. LVEF < 40% as determined by a MUGA scan or echocardiography; Prolonged QT syndrome (or QTcF >470 msec at screening); acute myocardial infarction or acute coronary syndromes within 6 months; clinically significant cardiac arrhythmias; thromboembolic or cerebrovascular events within 6 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify